搜索结果


   JAK2

靶点ID:TCMBANKGE000297


靶点别名:JTK10; THCYT3


靶点描述:Janus kinase 2


染色体:9


染色体位置:9p24.1


靶点类型:protein-coding


HERB_ID:-


HGNC_Link:6192


OMIM_Link:147796


Ensembl_Link:ENSG00000096968


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
TCMBANKHE003799 Fructus Forsythiae 连翘 To remove toxic heat, to cause subsidence of sweeling,and to eliminate modulation./Influenza in early stage, common cold in early stage, wind-heat common cold, encephalitis, hepatitis, tuberculosis, warm disease, heat strangury with inhibited pain, welling abscess, welling abscess and flat abscess, toxin swelling, scrofula, goiter and tuberculosis, throat impediment. dried fruit

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000006 evodiamine l-Evodiamine; BDBM50366821; BB_NC-1930; ZINC00898159; Evodiamine, <i>Evodia rutaecarpa; evodiamine ; 518-17-2; CHEMBL486598; Evodiamine; ZINC2031813; C09187 C19H17N3O 303.36 CN1C2C3=C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5N3
TCMBANKIN000055 seselin 8,8-Dimethyl-2H,8H-pyrano[2,3-f]chromen-2-one #; Amyrolin; ZINC265504; 8,8-Dimethyl-2H,8H-pyrano[2,3-f]chromen-2-one; 8,8-Dimethyl-2H,8H-benzo(1,2-b:3,4-b')dipyran-2-one; ACM523591; 5634E8957P; MCULE-7289743021; Sesalin; 8,8-DIMETHYLPYRANO[2,3-H]CHROMEN-2-ONE; 8,8-Dimethyl-2H,8H-Benzo[1,2-b:3,4-b']dipyran-2-one; 8,8-dimethylpyrano[2,3-f]chromen-2-one; 523-59-1; 8,8-Dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-2-one, 9CI; 2H,8H-Benzo[1,2-b:3,4-b']dipyran-2-one, 8,8-dimethyl-; AC1L29B1; CHEMBL71358; 2H,8H-Benzo(1,2-b:3,4-b')dipyran-2-one, 8,8-dimethyl-; Oprea1_187929; CTK4J5797; BDBM50361397; C09312; HMS1648A10; 2H-1-Benzopyran-6-acrylic acid, 5-hydroxy-2,2-dimethyl-, .delta.-lactone; Seseline; UNII-5634E8957P; DTXSID60200322; Pyranocoumarin deriv.; seselin ; AC1Q6BHE; CHEBI:69040; SCHEMBL8993385; 3',4'-Di-O-(-)-Camphanoyl-(+)-cis-khellactone; QUVCQYQEIOLHFZ-UHFFFAOYSA-N; STOCK1N-00353; Seselin; AKOS000276897; 8,8-dimethylpyrano[2,3-f]chromen-2(8H)-one C14H12O3 228.24 g/mol CC1(C=CC2=C(O1)C=CC3=C2OC(=O)C=C3)C
TCMBANKIN000083 Decursin decursin; C09258; SMR001397016; MLS002472905; CHEMBL1715398; [(7S)-8,8-dimethyl-2-oxo-6,7-dihydropyrano[5,6-g]chromen-7-yl] 3-methylbut-2-enoate; NCGC00247453-01; Decursinol angelate; (S)-7,8-Dihydro-8,8-dimethyl-2-oxo-2H,6H-benzo(1,2-b:5,4-b')dipyran-7-yl 3-methyl-2-butenoate; 5928-25-6; HMS2198C14; decursin ; 3-methylbut-2-enoic acid [(7S)-8,8-dimethyl-2-oxo-6,7-dihydropyrano[5,6-g]chromen-7-yl] ester; 3-methylbut-2-enoic acid [(7S)-2-keto-8,8-dimethyl-6,7-dihydropyrano[5,6-g]chromen-7-yl] ester; 2-Butenoic acid, 3-methyl-, 7,8-dihydro-8,8-dimethyl-2-oxo-2H,6H-benzo(1,2-b:5,4-b')dipyran-7-yl ester, (S)- C19H20O5 328.36 CC(=CC(=O)OC1CC2=C(C=C3C(=C2)C=CC(=O)O3)OC1(C)C)C
TCMBANKIN016721 phorbol diester CCCC(=O)OC1C(C2(C(C=C(CC3(C2C=C(C3=O)C)O)CO)C4C1(C4(C)C)OC(=O)CCC)O)C
TCMBANKIN021186 hexitol Allitol; ZINC03831017; InChI=1/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H; 488-44-8; (2R,3R,4S,5S)-hexane-1,2,3,4,5,6-hexol; GALACTITOL (D) C6H14O6 182.17 C(C(C(C(C(CO)O)O)O)O)O
TCMBANKIN025270 araban CN(C)C(=S)SSC(=S)N(C)C
TCMBANKIN037721 Jasminoidin C17H24O10 388.366 C1(C(=O)OC([H])([H])[H])=C([H])O[C@@]([H])(O[C@@]2([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O2)[C@]([H])(C(C([H])([H])O[H])=C([H])C3([H])[H])[C@@]13[H]
TCMBANKIN040323 Auxin A 328.4 g/mol
TCMBANKIN057980 l-alpha,gamma-diaminobutyric acid H-Dab-OH; L-2,4-diaminobutyrate; PDSP2_000140; HY-101414; L-DABA; AmbotzHAA1224; Butanoic acid, 2,4-diamino-, (2S)-; L-2,4-Diaminobutanoate; C-09303; AC1Q5QMH; L-alpha,gamma-Diaminobutyric acid; AKOS017344502; (2S)-2,4-diaminobutanoic acid; CCG-36519; (S)-2,4-diamino-Butanoate; NCIStruc1_000167; 1758-80-1; 2,4-Diaminobutyrate; alpha,gamma-Diaminobutyrate; BDBM92987; ZINC52986906; DB03817; AN-49841; (S)-2,4-Diaminobutanoic acid; NCGC00013478; EN300-119052; UNII-92V7KM11ZK component OGNSCSPNOLGXSM-VKHMYHEASA-N; UNII-61HPH2F0W7; L-2,4-diamino-Butyric acid; OGNSCSPNOLGXSM-VKHMYHEASA-N; L-diaminobutyric acid; CHEMBL321357; (S)-2,4-diamino-Butanoic acid; NCIStruc2_000050; NCI41117; PDSP1_000141; MolPort-008-267-988; NSC-41117; AC1L34P9; CHEBI:48950; L-Dbu; Butanoic acid, 2,4-diamino-, (S)-; 61HPH2F0W7; CC-29888; L-2,4-diaminobutyric acid; 83D096; L-2, 4-diaminobutyric acid; L-2,4-Diamino-n-butyric acid; Diaminobutyric acid, L-; (S)-2,4-Diaminobutyric acid; H-L-Dab-OH; C03283; AK170036; 2,4-Diaminobutanoate; NCGC00013478-02; FCH833652; L-2,4-diaminobutanoic acid; NCGC00096593-01; SCHEMBL34706; CS-6314; I14-15389; BD211196-6739-4CDA-8627-C1676AC86B43; l-α, γ-diaminobutyricacid C4H10N2O2 118.13 g/mol C(CN)C(C(=O)O)N
TCMBANKIN057984 PG ST5214535; 504-63-2; .beta.-Propylene glycol; PDO; C02457; InChI=1/C3H8O2/c4-2-1-3-5/h4-5H,1-3H; 2-Deoxyglycerol; .omega.-Propanediol; 1,3-Dihydroxypropane; BRN 0969155; Propane-1,3-diol; Trimethylene glycol; beta-Propylene glycol; CHEBI:16109; 2-(Hydroxymethyl)ethanol; 1,3-Propylenediol; 533734_ALDRICH; 81780_FLUKA; 1,3-PROPANDIOL; 4-01-00-02493 (Beilstein Handbook Reference); AI3-01851; NSC 65426; P50404_ALDRICH; 1,3-Propylene glycol; omega-Propanediol; EINECS 207-997-3; 1,3-Propanediol; ZINC01529437; NSC65426; 757125-93-2;1,3-propanediol C3H8O2 76.09 C(CO)CO
TCMBANKIN058057 D-Chiro-Inositol Chiro-inositol;mesoinositol; Myo-inositol; i-inositol; Inositol-c; scyllo-insitol; Inositol;KS-00001292; TR-022051; BG01505581; MFCD01321249; CTK1C5947; AKOS024318869; INOSITOL (D); Inositene; CHEBI:27374; D-(+)-chiro-Inositol; LT03328768; I-6500; 2H3; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; D07CPO; W-203081; NCGC00178580-01; ZINC103574430; Myoinositol; ZINC100019018; NSC-103959; SCHEMBL13114116; UNII-1VS4X81277; 12513-EP2292610A1; AKOS015912934; NSC25142; Inosite; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; BG00909558; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; BG01505582; NSC-127230; AK307531; Inositol, cis-; NSC 8101; 643-12-9; CHEBI:23311; MolPort-001-785-905; NSC-404118; KB-296111; 12513-EP2316831A1; K572; MolPort-003-719-862; Inositol, chiro-; Inositol (VAN8C; Isoinositol; I14-47230; GTPL4645; s4530; EINECS 211-394-0; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; CHEBI:22357; AK324051; Inositol [USAN:NF]; bmse000922; CDAISMWEOUEBRE-OQYPVSDDSA-N; DSSTox_RID_76890; NCGC00255362-01; 1VS4X81277; 1D-Chiro-inositol; chiro-inositol; BG01505565; 488-55-1; BG01505566; AKOS015960429; NSC103959; 576-63-6; SBI-0051369.P003; 1,2,4,5/3,6-cyclohexanehexol; I14-2742; 12513-EP2277880A1; AKOS015960633; J101.891D; A834712; Scyllitol; CHEBI:23927; KM0846; 1,2,3,4,5,6-Hexahydroxycyclohexane; Spectrum3_001053; HMS2091N13; MLS001332378; MolPort-001-742-552; NCIOpen2_008191; Cocositol; Phaseomannitol; Scyllite; myo-Inositol, 98% 100g; BSPBio_002606; KBio2_002075; FT-0693614; Inositol, United States Pharmacopeia (USP) Reference Standard; TR-017741; CCRIS 6745; STL453612; ZINC253837650; I0631; D03SHD; SCHEMBL6791918; 3635-EP2292088A1; AB00051982_13; CHEBI:17268; TR-022053; Iso-inositol; MFCD00077932; CTK8B3795; myo-Inositol, >=99%; GTPL4495; C19891; KSC225S4P; ZINC100073149; DSSTox_GSID_23146; MLS001335965; TL8004551; SMR000857319; bmse000102; AJ-26654; 887751-76-0; DB03106; UNII-9O6Y5O4P9W; 38876-99-2; myo-Inositol, BioUltra, >=99.5% (HPLC); Inositol, neo-; Matezodambose; 6R79WV4R10; I0040; Mesol; W-203392; NSC404118; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; Rat antispectacled eye factor; Inositol FCC; 3635-EP2305682A1; 1,2,3,5/4,6-Cyclohexanehexol; BG01505593; cis-Inositol, >=98.0% (TLC); Tox21_302035; CDAISMWEOUEBRE-LOLGQZEGSA-N; 643-10-7; AKOS027327401; 1,2,4/3,5,6-Hexahydroxycyclohexane; 3635-EP2295417A1; CHEMBL278373; FT-0652045; 3635-EP2305677A1; 1,2,3,4,5,6-Cyclohexanehexol; Neo-inositol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Q-201583; Hexahydroxycyclohexane; SCHEMBL187278; (1S,2S,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; CHEMBL1231671; EINECS 207-682-0; I14-47232; 1D-myo-Inositol; CHEMBL468154; SCHEMBL13058696; SC-18136; 3635-EP2280282A1; DB13178; 3635-EP2289886A1; Spectrum_001595; Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; NSC-757076; AKOS006240678; I14-60538; 12513-EP2374790A1; CJ-23964; AK102790; UNII-63GQX5QW03; INS; 87-89-8; Scyllite (for the structural isomer scyllo-Inositol); 2os9; CHEMBL1222251; I14-47231; MLS001335966; (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; alloinositol; ANW-43204; 4irx; KS-1420; Inositol (VAN); inositols; 4L6452S749; C06153; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inosital; ZINC100037751; AB0014290; MEGxp0_001817; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inositol, myo-; ELND 005; 13719-EP2311831A1; cyclohexane-1,2,3,4,5,6-hexol; FT-0627237; AKOS015912905; KS-0000146H; (+)-Chiro-Inositol; AC1L1A9E; L-(-)-chiro-Inositol, 95%; (1R,2R,3R,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture; 3635-EP2305636A1; C06151; 12513-EP2292597A1; myo-Inositol, purum, >=98.0% (HPLC); Inositol, scyllo-; MFCD00799555; 12513-EP2298768A1; NSC-25142; 1,2,3/4,5,6-cyclohexanehexol; MFCD00799556; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; ST24024704; Inositol, myo- (8CI); SCHEMBL13114115; GTPL4649; Bios I; M01914; ST50406013; NSC127230; FT-0632209; ZINC250615063; AC1Q2AJJ; SR-05000001655; Mesoinosite; Muscle sugar; ZINC102201844; 6917-35-7; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; 3635-EP2308879A1; Insitolum; D-myo-Inositol, Cell Culture Grade; I0630; Spectrum4_001193; epi-Cyclohexanehexol; SCHEMBL187796; NSC-45517; CDAISMWEOUEBRE-GPIVLXJGSA-N; 488-54-0; CC-093; 40032-EP2298312A1; ZINC1530357; 13719-EP2308875A1; CHEBI:27987; AN-24133; epi-Inositol; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Pharmakon1600-01500352; CDAISMWEOUEBRE-GNIYUCBRSA-N; Tox21_111642; UNII-6R79WV4R10; 13719-EP2316836A1; SMR000857145; HMS2230N03; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; mesoinositol; NCGC00159409-04; CHEBI:27372; CJ-05199; SCHEMBL6378921; AK115152; (1/4) inverted exclamation markIC; SCHEMBL491333; myo-Inositol, Vetec(TM) reagent grade, 99%; 3635-EP2275412A1; ELND005; NCGC00169828-01; I0632; EINECS 207-681-5; 3635-EP2295437A1; SCHEMBL14542470; MolPort-003-848-190; Muco-Inositol; D0Y4UQ; Epi-inositol, 98%; 1,2,3,4,5,6/0-cyclohexanetetrol; Mesovit; D-chiro-Inositol, >=98.0% (HPLC); TRA-0204644; 36190-90-6; NSC 25142; cis-Inositol; (1R,2R,3S,4R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; SCHEMBL12377889; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; i-Inositol; L-Inositol; CHEBI:10642; 12513-EP2305825A1; Chiro-inositol, (-)-; Inositol, muco-; Quercinitol; M94176HJ2F; HY-B1411; SCHEMBL12711208; SCHEMBL13580047; CDAISMWEOUEBRE-CDRYSYESSA-N; scyllo-Cyclohexanehexol; ZINC101185827; Allo-inositol; Tox21_111642_1; HMS3373E05; 1,3,5/4,6-Cyclohexanehexol; EINECS 209-000-7; KS-1284; W-203168; 13719-EP2280010A2; Phaseomannite; EPIINOSITOL; (+)-Epi-Inositol; NSC45517; Inositol (NF); 6643AB; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; SCHEMBL4748543; AK307315; 13719-EP2269977A2; 488-58-4; UNII-M94176HJ2F component CDAISMWEOUEBRE-LKPKBOIGSA-N; cis-1,3,5-trans-4,6-Cyclohexanehexol; SCHEMBL13114128; SCHEMBL6468882; UNII-587A93P465; scyllo-Inositol, >=98%; SMR000857320; D-chiro Inositol; AZD 103; SCHEMBL188237; SCHEMBL12411898; bmse000113; epi-Inositol, >=98.0% (HPLC); MLS001335967; 19030-27-4; AK307406; INOSITOL (L); KBio2_007211; Cyclohexane-1,2,3,4,5,6-hexaol; 41546-34-3; (1S,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; NSC8101; NSC-55551; 63GQX5QW03; (1R)-Cyclohexane-1r,2c,3t,4c,5t,6t-hexaol; myo -Inositol; ZINC306121118; D08DXZ; ST24049158; AX8234329; Inositol, epi-; TRA0065469; 551-72-4; 488-59-5; NSC55551; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 3635-EP2298312A1; Myoinosite; HMS2235M23; NSC-55552; Inositol [Nonspecific isomer]; A836375; SR-05000001655-5; myo-Inositol, SAJ special grade, >=99.0%; 13719-EP2298734A2; D-chiro-Inositol; HMS2235H05; AN-18118; (1S,2R,4R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; KBio3_001826; Inositol, meso-; ZINC103574467; AS-10616; CAS-87-89-8; Inositina; SCHEMBL959404; I0629; BG00909545; AmbotzGBB1246; EINECS 211-393-5; 1,3,5/2,4,6-cyclohexanehexol; EINECS 201-781-2; SCHEMBL5831; Meat sugar; neoinositol; 9O6Y5O4P9W; (-)-chiro-Inositol; 13719-EP2289891A2; AKOS015895894; 13719-EP2295437A1; (-)-Inositol; NSC55552; Cyclohexanehexol; Inosital (TN); Levoinositol; FT-0632208; BG01505583; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; TL8004550; L-chiro-Inositol; Myo inositol; Spectrum5_000961; (1R,2S,3S,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol; myo-inositol; (1S,2R,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; MFCD00272608; MLS001332377; D08079; SCHEMBL12371461; meso-Inositol; D-myo-Inositol; Cyclohexitol; ZINC100018867; 1,2,3,4/5,6-cyclohexanehexol; D-(+)-chiro-Inositol, 95%; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; ACon1_002457; KBioGR_001885; NSC-8101; TR-019452; FT-0670357; AKOS015994742; ZINC100032893; NSC757076; CS-4782; allo-Inositol, 97%; AN-23658; Mesoinosit; KS-00000QA9; AKOS027320475; KBio2_004643; ZINC103574475; UNII-4L6452S749; SCHEMBL5969; ZINC100055570; 1,3,5/2,4,6-Hexahydroxycyclohexane; KS-000017FC; 3635-EP2298775A1; bmse000901; FCH1118762; NCGC00159409-03; R1Y9F3N15A; I14-101844; myo-Inositol, for microbiology, >=99.0%; I0633; Dambose; myo-Inositol, PharmaGrade, meets FCC testing specifications, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.; FT-0693444; 1-L-chiro-Inositol; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; SR-05000001655-1; SCHEMBL188106; L-(-)-chiro-Inositol; L-myo-Inositol; 1,2,3,4,5,6-Cyclohexanehexaol; UNII-M94176HJ2F component CDAISMWEOUEBRE-SHFUYGGZSA-N; ZINC100513675; 173524-45-3; 643C129; NSC-55558; CCG-36096; Mouse antialopecia factor; FT-0632730; NSC55558; 8LQ63P85IC; I0628; MolPort-006-111-433; NCI60_041778; CDAISMWEOUEBRE-NIPYSYMMSA-N; KBioSS_002075; C00137; CBU; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; UNII-R1Y9F3N15A; D0B1EY; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; MolPort-003-933-930; 587A93P465; CHEBI:25492; NSC 404118; UNII-M94176HJ2F; MCULE-2727773046; J101.890F; HMS3369F20; SCHEMBL5832; UNII-8LQ63P85IC; 12513-EP2277881A1; UNII-4661D3JP8D; 53319-35-0; MLS001335968; 1,2,3,4,5,6-Cyclohexanehexol #; myo-Inositol, p.a., 98.0%; meso-(1/4) inverted exclamation mark (1/4); AC-11070; SCHEMBL959405; NCGC00178580-03; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; I06-1350; 1L-Chiro-inositol; SCHEMBL1055883; Nucite; LS-2350; RP24128; 1,2,3,4,5/6-cyclohexanehexol; GTPL4648; Epitope ID:144993; SCHEMBL12735687; AKOS006332036; Inositol NF 12; MFCD00003863; AK546883; 1,2,4/3,5,6-cyclohexanehexol; 13719-EP2298775A1; EINECS 230-024-9; W-202862; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; NCGC00159409-02; 4661D3JP8D; 1L-myo-Inositol; Scyllo-inositol; C06152; Chiro-inositol, (+)-; Inositol, i-; CHEMBL1950780; 1,2,3,4,5,6-cyclohexanhexol; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); D-(+)-Chiro Inositol; SC-91157; KS-00001315; NP-010162; I14-47229; VC30505; 4CH-024633; KB-251247; MFCD00065455; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; CDAISMWEOUEBRE-UHFFFAOYSA-N; ZINC100024490; Inositol, allo-; AI3-16111; Ambap6917-35-7; HMS3369B06; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; 1,3,4,5,6-Cyclohexanehexol; inositol; W-202861; SCHEMBL187397; DSSTox_CID_3146; ZINC100035580; 40032-EP2311830A1; 12513-EP2298744A2; K-9876; INOSITOL, MESO; CHEBI:24848; bmse000103; TR-016439; SCHEMBL13207905; (+)-Inositol; CHEMBL122705;cocositol;D-myo-inositol C6H12O6 180.16 g/mol C1(C(C(C(C(C1O)O)O)O)O)O
TCMBANKIN058192 isoliquiritigenin HCC; KBio2_000625; SPBio_000949; Spectrum2_000875; 961-29-5; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-HYDROXYPHENYL)-; SPECTRUM1504200; Chalcone, 2',4,4'-trihydroxy-; CHEMBL1395334; KBio3_002631; NCGC00015556-01; SDCCGMLS-0066751.P001; ST5309279; (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; KBio2_003193; InChI=1/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; CMLD3_000056; BSPBio_003411; C08650; CCRIS 7676; 2',4,4'-Trihydroxychalcone; Lopac0_000681; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; I159_SIGMA; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; Lopac-I-3766; CPD-3041; KBio1_001802; MEGxp0_001326; ZINC3869607; BRN 1914295; MLS000438943; SMR000112969; Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxyphenyl)-; (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; ACon1_000047; GU 17; KBioGR_002232; DivK1c_006858; KBio2_005761; 1-08-00-00707 (Beilstein Handbook Reference); 4,2&#8242;,4&#8242;-Trihydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; NCGC00090504-01; (Z)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; EU-0100681; Spectrum3_001656; AC1O7G44; 4,2',4'-Trihydroxychalcone; EINECS 237-316-5; I3766_SIGMA; AIDS035379; AIDS-035379; 13745-20-5; Spectrum5_000612; 2-propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-; Spectrum_000145; KBioSS_000625; Isoliquiritigenin; Spectrum4_001756; 42'4'-trihydroxychalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (E)-; NCGC00090504-03; SpecPlus_000762; 2',4',4-trihydroxychalcone C15H12O4 256.25 g/mol C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O
TCMBANKIN058205 trans-resveratrol (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4&prime;,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4&prime; NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4&prime;,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4&#8242;,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene C14H12O3 228.24 g/mol C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN058247 Phloretol Phloretin; EU-0101012; Dihydronaringenin; KBioGR_001803; 3-(4-Hydroxy-phenyl)-1-(2,4,6-trihydroxy-phenyl)-propan-1-one; CCRIS 7459; BCBcMAP01_000040; SDCCGMLS-0066637.P001; .beta.-(p-Hydroxyphenyl)phloropropiophenone; SMP1_000238; 79310_FLUKA; NCGC00094304-03; AIDS-052153; 2',4',6'-Trihydroxy-3-(p-hydroxyphenyl)propiophenone; Propiophenone, 2',4',6'-trihydroxy-3-(p-hydroxyphenyl)- (8CI); DivK1c_006429; KBioSS_001775; NSC 407292; CHEBI:17276; KBio3_002071; EINECS 200-488-7; KBio2_006911; P7912_SIGMA; AIDS052153; KBio1_001373; Spectrum3_001036; 2',4',6'-Trihydroxy-3-(4-Hydroxyphenyl)propiophenone; beta-(4-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; Spectrum5_001698; 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone; Lopac0_001012; Spectrum2_000681; Lopac-P-7912; NCGC00015840-01; beta-(p-Hydroxyphenyl)phloropropiophenone; SMR000326783; G50; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one; SPECTRUM300554; 2&#8242;,4&#8242;,6&#8242;-Trihydroxy-3-(4-hydroxyphenyl)propiophenone; beta-(p-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; MLS000728507; KBio2_004343; Propiophenone, 2',4',6'-trihydroxy-3-(p-hydroxyphenyl)-; Oprea1_824722; TNP00255; 60-82-2; SpecPlus_000333; NCGC00015840-02; 2&prime;,4&prime;,6&prime;-Trihydroxy-3-p-hydroxyphenylpropiophenone; ST057164; BSPBio_002851; KBio2_001775; NCGC00094304-02; C00774; ZINC00047553; SPBio_000801; Spectrum_001295; 1-Propanone, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-; Spectrum4_001172; NSC407292; .beta.-(p-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; phloretin C15H14O5 274.27 g/mol C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O
TCMBANKIN058374 Indolyl acetic acid 3-indolylaceticacid;Indole acetic acid;IES;heteroauxin;1H-Indole-3-acetic acid (9CI); beta-Indoleacetic acid; 54692-39-6; I8262_SIGMA; CHEBI:16411; 87-51-4; 1H-indol-3-ylacetic acid; CCRIS 1014; Heteroauxin; InChI=1/C10H9NO2/c12-10(13)5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H,12,13; 1H-Indole-3-acetic-a-t acid (9CI); EPA Pesticide Chemical Code 128915; EU-0099905; Indole-3-acetic acid-carboxy-14C; Acetic acid, indolyl-; beta-Indolylacetic acid; I3750_ALDRICH; omega-Skatole carboxylic acid; 2-(1H-Indol-3-yl)acetic acid; .beta.-Indole-3-acetic acid; MLS001066408; I2886_SIGMA; C00954; Hexteroauxin; .beta.-Indolylacetic acid; Indol-3-ylacetic acid; Rhizopin; Indole-3-acetic acid (8CI); [3H]-IAA; NSC 3787; Indole-3-acetic-t acid; WLN: T56 BMJ D1VQ; 3-(Carboxymethyl)indole; .alpha.-Indol-3-yl-acetic acid; 45533_RIEDEL; (1H-Indol-3-yl)acetic acid; ST5308201; .omega.-Skatole carboxylic acid; Maybridge1_006755; IAA; SDCCGMLS-0066204.P001; beta-IAA; Indoleacetic acid (VAN); 3-IAA; 3-Indolylacetic acid; 6305-45-9; Indolyl-3-acetic acid; 3-Indolylessigsaeure; Oprea1_602123; indole-3-acetic acid; IAC; Rhizopon A; Kyselina 3-indolyloctova [Czech]; 2-(3-Indolyl)acetic acid 3-(Carboxymethyl)-1H-indole; 1H-Indole-3-acetic acid; 3-Indolylmethylcarboxylic acid; .beta.-IAA; AIDS009893; SMR000471855; SR-01000596909-2; EINECS 201-748-2; 2-(1H-indol-3-yl)ethanoic acid; alpha-IAA; Heteroauxinhexteroauxiniaa; .alpha.-IAA; indoleacetic acid; 2-(indol-3-yl)ethanoic acid; 3-Indoleacetic acid; NSC3787; .beta.-Indoleacetic acid; AIDS-009893; AI3-24131 C10H9NO2 175.18 g/mol C1=CC=C2C(=C1)C(=CN2)CC(=O)O
TCMBANKIN059432 sanshool C16H25NO 247.38 CC=CC=CC=CCCC=CC(=O)NCC(C)C
TCMBANKIN059452 ethyl aldehyde C2H4O 44.05 g/mol CC=O
TCMBANKIN059928 emodin C15H10O5 270.24 g/mol CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O
TCMBANKIN060111 17alpha-estradiol C18H24O2 272.4 g/mol CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O
TCMBANKIN060910 cis-9-hexadecenoic acid C16H30O2 254.41 g/mol CCCCCCC=CCCCCCCCC(=O)O
TCMBANKIN061038 Gaidic acid C16H30O2 254.41 g/mol CCCCCCCCCCCCCC=CC(=O)O
TCMBANKIN061570 curcumin (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; Curcumin; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; Kacha haldi; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; ZINC00899824; 458-37-7; SDCCGMLS-0066836.P001; SCHEMBL2622435; Spectrum3_001990; DivK1c_006683; KBio1_001627; SpecPlus_000587; SPBio_001728; Spectrum2_001714; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; NSC32982; Turmeric oleoresin (79%-85% curcumin); Yellow Root; Halad; Diferaloylmethane; kachs haldi; safra d'inde; Curcumin, 95% (total curcuminoid content), from Turmeric rhizome; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; GTPL7000; Turmeric, oleoresin; CI 75300; MFCD00008365; curcuma longa l. root oil hydrodistilled; DSSTox_CID_1421; NSC-687842; C21H20O6; Merita earth; NCGC00017159-11; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-06; I06-2497; BDBM50140172; I14-19358; MLS001148449; LS-125; NCGC00023332-04; SCHEMBL8441; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; BIDD:ER0479; 458-37-7; Turmeric root oil; Tox21_111505; BDBM50067040; 1790-EP2308861A1; Safran d'Inde; Turmeric oil (Curcuma longa L.); NSC 687842; Tumeric yellow; NCGC00017159-05; Curcuma oil; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; EINECS 207-280-5; 15845-47-3; E 100; Curcuma longa l. oleoresin; Curcuma longa l. root oleoresin; SR-01000000149-2; NCGC00017159-10; D0H8LC; HMS3649K06; Turmeric oleoresin; Orange Root; Curcumin (Natural); Indian saffron; Curcumin, United States Pharmacopeia (USP) Reference Standard; NCGC00017159-07; CCG-36107; Curcumin solution, ~0.1 % (w/v) (in ethanol with 2M HCl (99:1 v/v)), for TLC derivatization; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcurmin; 1,5-Di(vanillyliden)acetylaceton; I06-0010; Natural yellow 3; SMR000058237; cid_969516; Zlut prirodni 3; CHEMBL140; CAS-458-37-7; Curcumin, analytical standard; BG0601; ZX-AT003872; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; BCP9000557; Yellow puccoon; Tumeric oleoresin; DB11672; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; BG00706978; NSC687842; AC1LJ6T6; SCHEMBL8440; SR-01000000149; Tox21_201116; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; J10108; C.I. Natural Yellow 3; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin (synthetic); BIC8500; NCGC00017159-09; CCRIS 5804; NCGC00023332-05; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; W-5038; 1,7-DI(4-HYDROXY-3-METHOXYPHENYL)HEPTA-1,6-DIENE-3; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; FEMA No. 3086; 1790-EP2305629A1; BB_NC-01422; BC678109; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; Yellow Ginger; Diferuloylmethane; BRN 2306965; Bio-0677; AC1Q46A0; 98% curcurmin); cid_5281767; ZINC899824; Oils, galangal; 33171-04-9; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; curcuma longa l. root oil CO2 extract; Gelbwurz; OR24598; Oil of turmeric; Curcuma oil (Curcuma longa); MLS000069631; 1,5-Divanillyliden-2,4-pentandion; BDBM29532; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; UNII-IT942ZTH98; Yellow, Turmeric; BCP0726000035; Tox21_110803; KB-251224; CU-01000001305-2; Turmeric oil; HMS2233K04; D07SDQ; ST055629; Curcumin, primary pharmaceutical reference standard; CCG-36020; BRD-K07572174-001-19-6; MolPort-001-763-682; DSSTox_GSID_31077; DSSTox_RID_78861; Turmeric; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; NSC-32982; Kacha haldi; HY-N0005; Kurkumin [Czech]; Haldar; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; Turmeric (>98% curcurmin); GP8291; M212; Zlut prirodni 3 [Czech]; VFLDPWHFBUODDF-FCXRPNKRSA-N; LS-2189; Turmeric yellow; Turmeric extract (Curcuma longa L.); Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; TR-032605; Curcuma longa l. root oil; FEMA No. 3085; curouma; Tu rmeric root oil; Opera_ID_1627; AC-24238; 73729-23-4; Halud; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; RTR-032605; Yo-Kin; NCGC00023332-03; trans,trans-Curcumin; Curcuma longa l. oil; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; diferuloylmethan; cMAP_000052; N1839; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; BG01656528; Curcuma; CCRIS 3257; Diferulylmethane; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); NCGC00017159-04; SC-17381; BRD-K07572174-001-22-0; turmeric root oil hydrodistilled; Oils, curcuma; 458C377; Hydrastis; AK316302; Haldar, Souchet; Natural Yellow3; 4-08-00-03697 (Beilstein Handbook Reference); E 100 (Dye); 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; CS-1490; Indian turmeric; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); Kurkumin; Curcumin I; Souchet; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; HSDB 4334; Haidr; NCI-C61325; BBL027711; Golden seal; SCHEMBL13521974; CC0179; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; Terra Merita; NCGC00258668-01; SBB006495; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); STL371943; AN-23454; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 8024-37-1; Curcuma longa oils; 91884-86-5; AKOS001305497; BRD-K07572174-001-02-2; Turmeric extract; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); CI Natural Yellow 3; Cucurmin; CHEBI:3962; DTXSID8031077; DB-002681; Curcumine; Turmeric root oleoresin; curcumin; turmeric root oil CO2 extract; Curcumin, from Curcuma longa (Turmeric), powder; NCGC00017159-12; 79257-48-0; C.I. 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; NSC 32982; SR-01000000149-5, curcumine;curcumin IC21H20O6 368.4 g/mol COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O
TCMBANKIN061938 sulforathane sulforaphane C6H11NOS2 177.3 g/mol CS(=O)CCCCN=C=S

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000002 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI000009 Neoplasms Abnormality of the nervous system; Neoplasm Neoplastic Process disease
TCMBANKDI000011 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system; Constitutional symptom Sign or Symptom phenotype
TCMBANKDI000018 Digestive System Diseases; Neoplasms; Endocrine System Diseases Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI000023 Skin and Connective Tissue Diseases; Immune System Diseases Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI000049 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Disease or Syndrome disease
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000061 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process group
TCMBANKDI000064 Digestive System Diseases - Disease or Syndrome group
TCMBANKDI000076 Neoplasms - Neoplastic Process group
TCMBANKDI000088 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process group
TCMBANKDI000092 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI000239 - - Neoplastic Process disease
TCMBANKDI000294 Neoplasms - Neoplastic Process disease
TCMBANKDI000474 Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI000498 - - Neoplastic Process disease
TCMBANKDI000802 Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases Abnormality of the integument Finding phenotype
TCMBANKDI001279 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI001856 Pathological Conditions, Signs and Symptoms; Digestive System Diseases - Disease or Syndrome disease
TCMBANKDI001948 Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI001965 Immune System Diseases - Disease or Syndrome disease
TCMBANKDI002013 - - Neoplastic Process disease
TCMBANKDI002287 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process group
TCMBANKDI002512 Digestive System Diseases Abnormality of the digestive system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI002742 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system Disease or Syndrome group
TCMBANKDI002974 Neoplasms - Neoplastic Process disease
TCMBANKDI003179 Neoplasms - Neoplastic Process disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI003394 Pathological Conditions, Signs and Symptoms Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI003411 - - Disease or Syndrome disease
TCMBANKDI003733 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system Pathologic Function phenotype
TCMBANKDI003957 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the cardiovascular system Sign or Symptom phenotype
TCMBANKDI004054 Pathological Conditions, Signs and Symptoms - Neoplastic Process phenotype
TCMBANKDI004201 Digestive System Diseases; Wounds and Injuries - Injury or Poisoning disease
TCMBANKDI004255 - - Disease or Syndrome disease
TCMBANKDI004272 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI004474 Nutritional and Metabolic Diseases Abnormality of the musculature Pathologic Function phenotype
TCMBANKDI004940 - - Neoplastic Process disease
TCMBANKDI005094 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases Abnormality of the cardiovascular system Sign or Symptom phenotype
TCMBANKDI005132 Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI005527 Nutritional and Metabolic Diseases - Pathologic Function phenotype
TCMBANKDI006088 - - Neoplastic Process disease
TCMBANKDI006103 - - Neoplastic Process disease
TCMBANKDI006454 Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI006641 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI007028 Neoplasms; Respiratory Tract Diseases; Immune System Diseases; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI007091 Neoplasms - Neoplastic Process phenotype
TCMBANKDI007135 - - Disease or Syndrome disease
TCMBANKDI007182 Neoplasms; Hemic and Lymphatic Diseases Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process disease
TCMBANKDI007618 Hemic and Lymphatic Diseases Abnormality of blood and blood-forming tissues Disease or Syndrome phenotype
TCMBANKDI007679 Digestive System Diseases; Neoplasms - Neoplastic Process; Experimental Model of Disease disease
TCMBANKDI007737 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process disease
TCMBANKDI007795 Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI007816 - - Disease or Syndrome disease
TCMBANKDI007832 Cardiovascular Diseases - Disease or Syndrome phenotype
TCMBANKDI008445 - Constitutional symptom Sign or Symptom phenotype
TCMBANKDI008601 Neoplasms - Neoplastic Process disease
TCMBANKDI008674 Nervous System Diseases; Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI008901 Neoplasms - Neoplastic Process disease
TCMBANKDI009231 Pathological Conditions, Signs and Symptoms; Infections Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI009773 Pathological Conditions, Signs and Symptoms; Immune System Diseases; Hemic and Lymphatic Diseases Abnormality of the immune system; Abnormality of blood and blood-forming tissues Disease or Syndrome disease
TCMBANKDI009912 Pathological Conditions, Signs and Symptoms Abnormality of metabolism/homeostasis Sign or Symptom phenotype
TCMBANKDI010214 - - Neoplastic Process disease
TCMBANKDI011173 Neoplasms - Neoplastic Process disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI011758 - - Laboratory Procedure phenotype
TCMBANKDI012074 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of prenatal development or birth; Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI013347 Pathological Conditions, Signs and Symptoms Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI013405 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI013495 Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI013773 Pathological Conditions, Signs and Symptoms Constitutional symptom Sign or Symptom phenotype
TCMBANKDI013927 Respiratory Tract Diseases Abnormality of the respiratory system Pathologic Function phenotype
TCMBANKDI014088 Respiratory Tract Diseases; Cardiovascular Diseases Abnormality of the respiratory system; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI014645 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI014740 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system Disease or Syndrome phenotype
TCMBANKDI014800 Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI014925 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI015200 Neoplasms; Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI015238 Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI015290 Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of the cardiovascular system Pathologic Function disease
TCMBANKDI015449 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI015559 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI016133 - - Finding phenotype
TCMBANKDI016890 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017188 Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI017641 - - Neoplastic Process disease
TCMBANKDI017642 Neoplasms Abnormality of the integument; Neoplasm Neoplastic Process disease
TCMBANKDI017887 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI018151 Digestive System Diseases; Nutritional and Metabolic Diseases - Disease or Syndrome group
TCMBANKDI018635 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018731 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018837 Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases Abnormality of the immune system; Abnormality of blood and blood-forming tissues Disease or Syndrome disease
TCMBANKDI019825 Neoplasms - Neoplastic Process disease
TCMBANKDI020516 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI020602 Male Urogenital Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI020634 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI021293 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases Abnormality of the genitourinary system; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI021339 Hemic and Lymphatic Diseases Abnormality of blood and blood-forming tissues Disease or Syndrome group
TCMBANKDI021382 Pathological Conditions, Signs and Symptoms Abnormality of the integument Finding phenotype
TCMBANKDI021531 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome phenotype
TCMBANKDI023186 - Abnormality of metabolism/homeostasis Finding phenotype
TCMBANKDI024262 - - Neoplastic Process phenotype
TCMBANKDI024402 Hemic and Lymphatic Diseases Abnormality of metabolism/homeostasis; Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI024561 - - Neoplastic Process disease
TCMBANKDI024571 Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI024668 Musculoskeletal Diseases; Stomatognathic Diseases - Disease or Syndrome disease
TCMBANKDI025194 - - Finding disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI026399 - Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI026556 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI027026 Neoplasms; Skin and Connective Tissue Diseases - Neoplastic Process disease
TCMBANKDI027028 Digestive System Diseases; Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI027040 Immune System Diseases - Disease or Syndrome disease
TCMBANKDI027339 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process disease
TCMBANKDI027669 - - Finding phenotype
TCMBANKDI027805 - - Neoplastic Process disease
TCMBANKDI028231 - Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process disease
TCMBANKDI028701 Pathological Conditions, Signs and Symptoms Growth abnormality Finding phenotype
TCMBANKDI029321 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI029857 Neoplasms - Neoplastic Process disease
TCMBANKDI029861 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI029899 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI029962 - - Disease or Syndrome disease
TCMBANKDI030041 Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI030165 Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI030204 - - Neoplastic Process disease
TCMBANKDI030540 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI031189 Neoplasms Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI031190 Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI031192 Neoplasms; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI031297 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI031381 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI031495 Neoplasms; Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI031523 Hemic and Lymphatic Diseases Abnormality of blood and blood-forming tissues Disease or Syndrome disease
TCMBANKDI031651 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI031939 - - Disease or Syndrome disease
TCMBANKDI032163 Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI032204 - Abnormality of blood and blood-forming tissues Pathologic Function phenotype
TCMBANKDI032436 Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI032472 Pathological Conditions, Signs and Symptoms; Neoplasms; Nervous System Diseases - Neoplastic Process disease
TCMBANKDI032496 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI032498 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease